NEW YORK (GenomeWeb News) — Synthetic protein drug developer ProMetic Biosciences will develop a synthetic ligand affinity for Novartis, the company said today.
PBL, a subsidiary of ProMetic Life Sciences, said Novartis Vaccines has hired it to screen chemical libraries for ligands that may be used to purify a new vaccine product Novartis currently has in clinical trials.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.